Objective: Newborns are highly susceptible to bacterial sepsis. Mannan-binding lectin (MBL), M-, L- and H-ficolin recognize microorganisms and activate the complement system via MBL-associated ...
Omeros’ lead MASP-2 inhibitor narsoplimab targets the lectin pathway of complement and is the subject of a biologics license application pending before FDA for the treatment of hematopoietic ...
About Zaltenibart (OMS906) Zaltenibart is an investigational human monoclonal antibody targeting mannan-binding lectin ... activator of the complement system’s alternative pathway.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback